| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 141 | 2022 | 283 | 35.420 |
Why?
|
| Anti-Bacterial Agents | 60 | 2022 | 1026 | 8.330 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 9 | 2022 | 37 | 5.550 |
Why?
|
| Bronchiectasis | 13 | 2021 | 25 | 4.470 |
Why?
|
| Respiratory Tract Infections | 20 | 2021 | 91 | 4.280 |
Why?
|
| Pseudomonas Infections | 23 | 2022 | 83 | 4.170 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 22 | 2022 | 51 | 4.050 |
Why?
|
| Hemoptysis | 8 | 2021 | 28 | 3.320 |
Why?
|
| Lung Diseases | 9 | 2022 | 175 | 3.280 |
Why?
|
| Pseudomonas aeruginosa | 23 | 2022 | 133 | 3.190 |
Why?
|
| Aminophenols | 11 | 2022 | 19 | 3.060 |
Why?
|
| Pneumothorax | 8 | 2021 | 42 | 3.020 |
Why?
|
| Quinolones | 10 | 2021 | 60 | 2.730 |
Why?
|
| Disease Progression | 20 | 2021 | 1038 | 2.670 |
Why?
|
| Tobramycin | 9 | 2020 | 38 | 2.550 |
Why?
|
| Benzodioxoles | 8 | 2022 | 30 | 2.360 |
Why?
|
| Humans | 174 | 2022 | 68618 | 2.200 |
Why?
|
| Lung | 16 | 2022 | 849 | 2.170 |
Why?
|
| Biomedical Research | 5 | 2020 | 310 | 2.120 |
Why?
|
| Administration, Inhalation | 30 | 2021 | 187 | 1.820 |
Why?
|
| Nontuberculous Mycobacteria | 5 | 2022 | 22 | 1.790 |
Why?
|
| Periodicals as Topic | 4 | 2020 | 158 | 1.780 |
Why?
|
| Chloride Channel Agonists | 5 | 2021 | 6 | 1.680 |
Why?
|
| Forced Expiratory Volume | 20 | 2021 | 87 | 1.640 |
Why?
|
| Mutation | 15 | 2022 | 1213 | 1.630 |
Why?
|
| Publishing | 3 | 2020 | 89 | 1.440 |
Why?
|
| Respiratory Insufficiency | 4 | 2021 | 76 | 1.370 |
Why?
|
| Respiratory Function Tests | 18 | 2021 | 123 | 1.250 |
Why?
|
| Aminopyridines | 5 | 2019 | 26 | 1.240 |
Why?
|
| Ethics Committees, Research | 2 | 2018 | 22 | 1.200 |
Why?
|
| Lung Transplantation | 12 | 2018 | 88 | 1.190 |
Why?
|
| Adult | 71 | 2022 | 21403 | 1.170 |
Why?
|
| Chronic Disease | 12 | 2020 | 1330 | 1.150 |
Why?
|
| Levofloxacin | 6 | 2021 | 23 | 1.140 |
Why?
|
| Drug Resistance, Bacterial | 5 | 2020 | 98 | 1.120 |
Why?
|
| Female | 79 | 2022 | 38074 | 1.070 |
Why?
|
| Anti-Infective Agents | 4 | 2021 | 166 | 1.070 |
Why?
|
| Adolescent | 40 | 2022 | 8912 | 1.060 |
Why?
|
| Bacterial Infections | 2 | 2018 | 163 | 1.020 |
Why?
|
| Child | 33 | 2022 | 6405 | 1.020 |
Why?
|
| Indoles | 3 | 2021 | 146 | 1.010 |
Why?
|
| Male | 73 | 2021 | 37321 | 0.980 |
Why?
|
| Mannitol | 3 | 2021 | 25 | 0.960 |
Why?
|
| Respiratory Therapy | 6 | 2010 | 24 | 0.940 |
Why?
|
| Dry Powder Inhalers | 3 | 2021 | 4 | 0.890 |
Why?
|
| Aminoglycosides | 3 | 2022 | 54 | 0.860 |
Why?
|
| Meconium Ileus | 1 | 2022 | 3 | 0.820 |
Why?
|
| Treatment Outcome | 32 | 2022 | 7029 | 0.820 |
Why?
|
| Pneumonia | 1 | 2022 | 110 | 0.790 |
Why?
|
| Microbial Sensitivity Tests | 10 | 2020 | 226 | 0.770 |
Why?
|
| Aztreonam | 3 | 2016 | 6 | 0.760 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 4 | 2022 | 11 | 0.760 |
Why?
|
| Quality of Life | 10 | 2021 | 1515 | 0.760 |
Why?
|
| Needs Assessment | 2 | 2020 | 186 | 0.730 |
Why?
|
| Coinfection | 1 | 2020 | 30 | 0.710 |
Why?
|
| Risk | 1 | 2021 | 563 | 0.700 |
Why?
|
| Sputum | 10 | 2021 | 51 | 0.690 |
Why?
|
| Libraries, Medical | 1 | 2019 | 16 | 0.690 |
Why?
|
| Access to Information | 1 | 2019 | 21 | 0.680 |
Why?
|
| Cost of Illness | 1 | 2021 | 206 | 0.680 |
Why?
|
| Retrospective Studies | 16 | 2022 | 7277 | 0.660 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2019 | 157 | 0.650 |
Why?
|
| Hospitalization | 5 | 2022 | 978 | 0.650 |
Why?
|
| Mycobacterium avium Complex | 5 | 2022 | 16 | 0.640 |
Why?
|
| Clinical Trials as Topic | 5 | 2020 | 848 | 0.640 |
Why?
|
| Recovery of Function | 2 | 2018 | 506 | 0.620 |
Why?
|
| Genetic Carrier Screening | 1 | 2018 | 25 | 0.610 |
Why?
|
| Double-Blind Method | 14 | 2021 | 1738 | 0.610 |
Why?
|
| Siblings | 1 | 2018 | 34 | 0.600 |
Why?
|
| Authorship | 1 | 2017 | 18 | 0.600 |
Why?
|
| Young Adult | 18 | 2021 | 5717 | 0.600 |
Why?
|
| Editorial Policies | 1 | 2017 | 32 | 0.590 |
Why?
|
| Consensus | 3 | 2019 | 211 | 0.570 |
Why?
|
| Practice Guidelines as Topic | 6 | 2018 | 772 | 0.570 |
Why?
|
| Hypertension, Pulmonary | 1 | 2019 | 232 | 0.560 |
Why?
|
| Amikacin | 4 | 2021 | 13 | 0.550 |
Why?
|
| Bronchodilator Agents | 1 | 2016 | 43 | 0.540 |
Why?
|
| Time Factors | 19 | 2021 | 4655 | 0.530 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 92 | 0.530 |
Why?
|
| United States | 12 | 2021 | 7367 | 0.520 |
Why?
|
| Mass Screening | 2 | 2020 | 843 | 0.520 |
Why?
|
| Drug Combinations | 4 | 2021 | 304 | 0.510 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 207 | 0.510 |
Why?
|
| Antimicrobial Stewardship | 3 | 2020 | 33 | 0.500 |
Why?
|
| Mucociliary Clearance | 4 | 2017 | 21 | 0.500 |
Why?
|
| Administration, Intravenous | 7 | 2021 | 89 | 0.500 |
Why?
|
| Symptom Flare Up | 6 | 2020 | 20 | 0.490 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2021 | 2324 | 0.480 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2018 | 186 | 0.460 |
Why?
|
| Homozygote | 3 | 2015 | 119 | 0.460 |
Why?
|
| Child, Preschool | 10 | 2021 | 3187 | 0.460 |
Why?
|
| Physical Therapy Modalities | 1 | 2015 | 133 | 0.450 |
Why?
|
| Europe | 6 | 2021 | 196 | 0.450 |
Why?
|
| Drug Monitoring | 7 | 2021 | 107 | 0.450 |
Why?
|
| Societies, Medical | 1 | 2016 | 403 | 0.440 |
Why?
|
| Severity of Illness Index | 6 | 2021 | 1851 | 0.440 |
Why?
|
| Aerosols | 6 | 2016 | 42 | 0.430 |
Why?
|
| Research Design | 4 | 2023 | 729 | 0.430 |
Why?
|
| Registries | 4 | 2022 | 733 | 0.400 |
Why?
|
| Cohort Studies | 4 | 2021 | 2358 | 0.380 |
Why?
|
| Respiratory Tract Diseases | 2 | 2009 | 43 | 0.380 |
Why?
|
| Follow-Up Studies | 11 | 2020 | 3259 | 0.380 |
Why?
|
| Biomarkers | 4 | 2021 | 1593 | 0.360 |
Why?
|
| Voice Quality | 2 | 2020 | 21 | 0.360 |
Why?
|
| Cough | 4 | 2018 | 65 | 0.350 |
Why?
|
| Risk Assessment | 3 | 2015 | 2007 | 0.350 |
Why?
|
| Risk Factors | 10 | 2018 | 5731 | 0.340 |
Why?
|
| Transition to Adult Care | 1 | 2009 | 18 | 0.340 |
Why?
|
| Sweat | 3 | 2019 | 5 | 0.340 |
Why?
|
| Expectorants | 1 | 2009 | 5 | 0.340 |
Why?
|
| Infant, Newborn | 5 | 2022 | 2455 | 0.340 |
Why?
|
| Phenotype | 6 | 2023 | 947 | 0.340 |
Why?
|
| Middle Aged | 26 | 2021 | 21147 | 0.340 |
Why?
|
| Suction | 1 | 2009 | 33 | 0.340 |
Why?
|
| Exercise Therapy | 2 | 2009 | 183 | 0.330 |
Why?
|
| Social Responsibility | 2 | 2020 | 39 | 0.330 |
Why?
|
| Sleep Wake Disorders | 1 | 2009 | 94 | 0.310 |
Why?
|
| Molecular Targeted Therapy | 3 | 2018 | 170 | 0.310 |
Why?
|
| Medication Therapy Management | 3 | 2017 | 32 | 0.310 |
Why?
|
| Genotype | 3 | 2021 | 786 | 0.310 |
Why?
|
| Pediatrics | 2 | 2018 | 341 | 0.300 |
Why?
|
| Infant | 7 | 2018 | 2891 | 0.290 |
Why?
|
| Respiratory Mechanics | 3 | 1996 | 33 | 0.290 |
Why?
|
| Pleurodesis | 2 | 2021 | 11 | 0.290 |
Why?
|
| Chest Tubes | 2 | 2021 | 18 | 0.290 |
Why?
|
| Death | 1 | 2007 | 38 | 0.280 |
Why?
|
| Pregnancy | 3 | 2022 | 2334 | 0.270 |
Why?
|
| Patient Care Team | 2 | 2010 | 311 | 0.270 |
Why?
|
| Pain | 1 | 2009 | 472 | 0.260 |
Why?
|
| Prospective Studies | 9 | 2020 | 3705 | 0.260 |
Why?
|
| Dyspnea | 3 | 2017 | 87 | 0.260 |
Why?
|
| Bronchoscopy | 2 | 2021 | 147 | 0.250 |
Why?
|
| Nutritional Support | 2 | 2018 | 22 | 0.250 |
Why?
|
| Models, Organizational | 2 | 2019 | 97 | 0.250 |
Why?
|
| Scopolamine Derivatives | 1 | 2014 | 3 | 0.250 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 2279 | 0.250 |
Why?
|
| Forced Expiratory Flow Rates | 3 | 2015 | 5 | 0.240 |
Why?
|
| Administration, Oral | 2 | 2015 | 411 | 0.230 |
Why?
|
| Respiratory Muscles | 2 | 2020 | 9 | 0.230 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2012 | 234 | 0.230 |
Why?
|
| Noninvasive Ventilation | 2 | 2021 | 5 | 0.230 |
Why?
|
| Patient Selection | 3 | 2019 | 592 | 0.230 |
Why?
|
| Disaster Planning | 1 | 2005 | 105 | 0.230 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2021 | 32 | 0.230 |
Why?
|
| DNA Mutational Analysis | 3 | 2018 | 159 | 0.230 |
Why?
|
| Surveys and Questionnaires | 5 | 2020 | 2800 | 0.220 |
Why?
|
| North America | 2 | 2021 | 112 | 0.220 |
Why?
|
| Time | 2 | 2021 | 57 | 0.220 |
Why?
|
| International Cooperation | 2 | 2020 | 88 | 0.220 |
Why?
|
| Mental Processes | 1 | 2023 | 22 | 0.210 |
Why?
|
| Bacteria | 2 | 2018 | 193 | 0.210 |
Why?
|
| Symptom Assessment | 2 | 2020 | 33 | 0.210 |
Why?
|
| Quality Improvement | 2 | 2017 | 413 | 0.210 |
Why?
|
| Proof of Concept Study | 1 | 2022 | 38 | 0.210 |
Why?
|
| Internal Medicine | 1 | 2004 | 118 | 0.210 |
Why?
|
| Genetic Therapy | 2 | 2016 | 291 | 0.210 |
Why?
|
| Disasters | 1 | 2005 | 204 | 0.210 |
Why?
|
| Australia | 2 | 2021 | 235 | 0.210 |
Why?
|
| Terminally Ill | 1 | 2002 | 17 | 0.210 |
Why?
|
| Patient Care Management | 3 | 2017 | 40 | 0.210 |
Why?
|
| Attitude of Health Personnel | 2 | 2017 | 442 | 0.210 |
Why?
|
| Munchausen Syndrome | 1 | 2002 | 2 | 0.210 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 581 | 0.210 |
Why?
|
| Palliative Care | 2 | 2021 | 271 | 0.210 |
Why?
|
| Exocrine Pancreatic Insufficiency | 1 | 2022 | 6 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 786 | 0.210 |
Why?
|
| Narcotics | 1 | 2002 | 65 | 0.200 |
Why?
|
| Continuity of Patient Care | 1 | 2004 | 170 | 0.200 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2017 | 931 | 0.200 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 6 | 0.200 |
Why?
|
| Thoracostomy | 1 | 2021 | 6 | 0.200 |
Why?
|
| Total Lung Capacity | 3 | 2015 | 14 | 0.200 |
Why?
|
| Drug Delivery Systems | 2 | 2010 | 236 | 0.200 |
Why?
|
| Fetus | 1 | 2022 | 157 | 0.190 |
Why?
|
| Long Term Adverse Effects | 1 | 2021 | 6 | 0.190 |
Why?
|
| Ofloxacin | 2 | 2011 | 15 | 0.190 |
Why?
|
| Decision Making | 2 | 2018 | 410 | 0.190 |
Why?
|
| Israel | 1 | 2021 | 26 | 0.190 |
Why?
|
| Neonatal Screening | 2 | 2018 | 43 | 0.190 |
Why?
|
| Carrier State | 1 | 2021 | 39 | 0.190 |
Why?
|
| Surgical Instruments | 1 | 2021 | 44 | 0.190 |
Why?
|
| Drug Therapy, Combination | 4 | 2019 | 649 | 0.190 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 180 | 0.190 |
Why?
|
| Antifibrinolytic Agents | 1 | 2021 | 52 | 0.190 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2020 | 504 | 0.190 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2020 | 20 | 0.180 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2020 | 96 | 0.180 |
Why?
|
| Mothers | 1 | 2022 | 172 | 0.180 |
Why?
|
| Nitric Oxide | 1 | 2022 | 382 | 0.180 |
Why?
|
| Burkholderia Infections | 1 | 2020 | 4 | 0.180 |
Why?
|
| Acid Ceramidase | 1 | 2021 | 85 | 0.180 |
Why?
|
| Journal Impact Factor | 1 | 2020 | 12 | 0.180 |
Why?
|
| Burkholderia cepacia | 3 | 1994 | 3 | 0.180 |
Why?
|
| Open Access Publishing | 1 | 2020 | 1 | 0.180 |
Why?
|
| Prosthesis Implantation | 1 | 2021 | 83 | 0.180 |
Why?
|
| Lipid Metabolism | 1 | 2021 | 186 | 0.180 |
Why?
|
| Resistance Training | 1 | 2020 | 29 | 0.180 |
Why?
|
| Organizational Objectives | 1 | 2020 | 70 | 0.180 |
Why?
|
| Voice Disorders | 1 | 2020 | 22 | 0.180 |
Why?
|
| Congresses as Topic | 1 | 2020 | 85 | 0.180 |
Why?
|
| Antifungal Agents | 1 | 2020 | 108 | 0.180 |
Why?
|
| Incidence | 3 | 2015 | 1603 | 0.170 |
Why?
|
| Dronabinol | 1 | 2020 | 84 | 0.170 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 131 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2019 | 1745 | 0.170 |
Why?
|
| Models, Economic | 1 | 2019 | 69 | 0.170 |
Why?
|
| Delphi Technique | 3 | 2019 | 62 | 0.170 |
Why?
|
| Pulmonary Stretch Receptors | 2 | 1996 | 2 | 0.170 |
Why?
|
| Internationality | 1 | 2019 | 74 | 0.170 |
Why?
|
| Sphingosine | 1 | 2021 | 315 | 0.170 |
Why?
|
| Medicare | 1 | 2021 | 319 | 0.160 |
Why?
|
| Terminology as Topic | 1 | 2020 | 141 | 0.160 |
Why?
|
| Leadership | 1 | 2020 | 136 | 0.160 |
Why?
|
| Mycobacterium abscessus | 1 | 2018 | 1 | 0.160 |
Why?
|
| Immunocompetence | 1 | 2018 | 19 | 0.160 |
Why?
|
| Antiviral Agents | 1 | 2020 | 211 | 0.160 |
Why?
|
| Prognosis | 5 | 2019 | 2093 | 0.160 |
Why?
|
| Latent Tuberculosis | 1 | 2018 | 13 | 0.160 |
Why?
|
| Forecasting | 1 | 2019 | 277 | 0.160 |
Why?
|
| Sphingolipids | 1 | 2021 | 337 | 0.150 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 42 | 0.150 |
Why?
|
| Counselors | 1 | 2018 | 6 | 0.150 |
Why?
|
| Hearing Loss | 1 | 2020 | 154 | 0.150 |
Why?
|
| Human Experimentation | 1 | 2018 | 19 | 0.150 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2010 | 240 | 0.150 |
Why?
|
| Academies and Institutes | 1 | 2018 | 31 | 0.150 |
Why?
|
| Health Facilities | 1 | 2018 | 36 | 0.150 |
Why?
|
| Scientific Misconduct | 1 | 2017 | 12 | 0.150 |
Why?
|
| Genetic Counseling | 1 | 2018 | 45 | 0.150 |
Why?
|
| Microbiota | 1 | 2018 | 80 | 0.150 |
Why?
|
| North Carolina | 1 | 2018 | 224 | 0.150 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1553 | 0.150 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2017 | 10 | 0.140 |
Why?
|
| Membrane Transport Modulators | 1 | 2017 | 23 | 0.140 |
Why?
|
| Comorbidity | 1 | 2021 | 1426 | 0.140 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 186 | 0.140 |
Why?
|
| Endpoint Determination | 1 | 2017 | 82 | 0.140 |
Why?
|
| Genetic Testing | 1 | 2018 | 159 | 0.140 |
Why?
|
| Rifampin | 1 | 2017 | 45 | 0.140 |
Why?
|
| Drug Approval | 1 | 2017 | 50 | 0.140 |
Why?
|
| Universities | 1 | 2018 | 191 | 0.140 |
Why?
|
| Portugal | 1 | 2016 | 7 | 0.140 |
Why?
|
| Pharmacogenetics | 2 | 2017 | 47 | 0.140 |
Why?
|
| Spirometry | 2 | 2020 | 47 | 0.140 |
Why?
|
| Cause of Death | 3 | 2010 | 241 | 0.140 |
Why?
|
| Canada | 1 | 2017 | 267 | 0.140 |
Why?
|
| beta-Lactams | 2 | 2022 | 29 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 445 | 0.140 |
Why?
|
| Retreatment | 1 | 2016 | 59 | 0.140 |
Why?
|
| Drug Administration Schedule | 3 | 2017 | 567 | 0.130 |
Why?
|
| Patient Transfer | 2 | 2009 | 86 | 0.130 |
Why?
|
| Drug Discovery | 1 | 2017 | 94 | 0.130 |
Why?
|
| Patient Care Planning | 3 | 2017 | 108 | 0.130 |
Why?
|
| Aged | 8 | 2021 | 14862 | 0.130 |
Why?
|
| Paranasal Sinuses | 2 | 2008 | 165 | 0.130 |
Why?
|
| Staphylococcus aureus | 1 | 2017 | 175 | 0.130 |
Why?
|
| Liposomes | 3 | 2021 | 107 | 0.130 |
Why?
|
| Inhalation | 1 | 1995 | 11 | 0.130 |
Why?
|
| Precision Medicine | 1 | 2016 | 111 | 0.130 |
Why?
|
| Respiratory System Agents | 1 | 2015 | 4 | 0.130 |
Why?
|
| Body Height | 1 | 2015 | 67 | 0.130 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2015 | 61 | 0.130 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 215 | 0.120 |
Why?
|
| Pneumocystis carinii | 1 | 2014 | 5 | 0.120 |
Why?
|
| Parents | 1 | 2018 | 312 | 0.120 |
Why?
|
| Mycobacterium Infections | 1 | 2014 | 13 | 0.120 |
Why?
|
| United Kingdom | 1 | 2015 | 152 | 0.120 |
Why?
|
| Nutritional Status | 1 | 2015 | 112 | 0.120 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2014 | 57 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 767 | 0.120 |
Why?
|
| Aspergillosis | 1 | 1994 | 20 | 0.120 |
Why?
|
| Standard of Care | 1 | 2014 | 22 | 0.120 |
Why?
|
| Candidiasis | 1 | 1994 | 39 | 0.120 |
Why?
|
| Ceftazidime | 3 | 1999 | 12 | 0.120 |
Why?
|
| Premedication | 1 | 1994 | 49 | 0.120 |
Why?
|
| Health Status | 3 | 2014 | 429 | 0.120 |
Why?
|
| Telemedicine | 1 | 2022 | 700 | 0.120 |
Why?
|
| Ciliary Motility Disorders | 1 | 2013 | 3 | 0.120 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2013 | 10 | 0.120 |
Why?
|
| Cephalosporins | 3 | 1999 | 59 | 0.120 |
Why?
|
| Stress, Physiological | 1 | 1995 | 215 | 0.110 |
Why?
|
| Sensation | 1 | 1994 | 49 | 0.110 |
Why?
|
| Terminal Care | 3 | 2018 | 92 | 0.110 |
Why?
|
| Respiration | 1 | 1994 | 91 | 0.110 |
Why?
|
| Body Weight | 1 | 2015 | 554 | 0.110 |
Why?
|
| Prevalence | 2 | 2022 | 1619 | 0.110 |
Why?
|
| Pneumonia, Bacterial | 1 | 2012 | 19 | 0.110 |
Why?
|
| Respiration, Artificial | 1 | 1994 | 190 | 0.110 |
Why?
|
| Cilia | 1 | 2013 | 94 | 0.110 |
Why?
|
| Oxygen Consumption | 2 | 2009 | 258 | 0.110 |
Why?
|
| Veins | 1 | 2012 | 68 | 0.110 |
Why?
|
| Chlorides | 1 | 2012 | 68 | 0.110 |
Why?
|
| Self Report | 1 | 2014 | 371 | 0.100 |
Why?
|
| Inflammation | 1 | 2018 | 1030 | 0.100 |
Why?
|
| Psychometrics | 1 | 2014 | 514 | 0.100 |
Why?
|
| Alleles | 1 | 2012 | 386 | 0.100 |
Why?
|
| Bronchial Arteries | 1 | 2010 | 2 | 0.090 |
Why?
|
| Weight Lifting | 1 | 2010 | 15 | 0.090 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2010 | 21 | 0.090 |
Why?
|
| Aircraft | 1 | 2010 | 30 | 0.090 |
Why?
|
| Positive-Pressure Respiration | 1 | 2010 | 27 | 0.090 |
Why?
|
| Travel | 1 | 2010 | 38 | 0.090 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2010 | 4 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 1465 | 0.090 |
Why?
|
| Foundations | 1 | 2009 | 17 | 0.090 |
Why?
|
| Personal Autonomy | 1 | 2009 | 22 | 0.090 |
Why?
|
| Chest Wall Oscillation | 1 | 2009 | 7 | 0.080 |
Why?
|
| Professional-Patient Relations | 1 | 2009 | 71 | 0.080 |
Why?
|
| Powders | 3 | 2015 | 32 | 0.080 |
Why?
|
| Drug Synergism | 1 | 2009 | 260 | 0.080 |
Why?
|
| Secondary Prevention | 1 | 2010 | 291 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 301 | 0.080 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2008 | 117 | 0.080 |
Why?
|
| Embolization, Therapeutic | 1 | 2010 | 150 | 0.080 |
Why?
|
| Biological Availability | 2 | 2019 | 79 | 0.080 |
Why?
|
| Acute Disease | 1 | 2010 | 658 | 0.080 |
Why?
|
| Interprofessional Relations | 1 | 2009 | 188 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2022 | 2077 | 0.080 |
Why?
|
| Deoxyribonuclease I | 1 | 2007 | 16 | 0.080 |
Why?
|
| Health Surveys | 1 | 2009 | 489 | 0.070 |
Why?
|
| Length of Stay | 3 | 2022 | 780 | 0.070 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2007 | 56 | 0.070 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2007 | 30 | 0.070 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2006 | 15 | 0.070 |
Why?
|
| Clinical Protocols | 2 | 2017 | 172 | 0.070 |
Why?
|
| Health Care Surveys | 2 | 2004 | 239 | 0.070 |
Why?
|
| Obesity | 2 | 2022 | 1076 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 438 | 0.070 |
Why?
|
| Catheters, Indwelling | 1 | 2006 | 72 | 0.070 |
Why?
|
| Bacteriological Techniques | 2 | 2021 | 49 | 0.070 |
Why?
|
| Sodium Channels | 1 | 2005 | 24 | 0.070 |
Why?
|
| Social Support | 3 | 2018 | 423 | 0.060 |
Why?
|
| Oligospermia | 1 | 2005 | 1 | 0.060 |
Why?
|
| Hyperaldosteronism | 1 | 2005 | 5 | 0.060 |
Why?
|
| Acid-Base Equilibrium | 1 | 2005 | 10 | 0.060 |
Why?
|
| Alkalosis | 1 | 2005 | 5 | 0.060 |
Why?
|
| Mutagenesis, Insertional | 1 | 2005 | 24 | 0.060 |
Why?
|
| Hypokalemia | 1 | 2005 | 12 | 0.060 |
Why?
|
| Patient Education as Topic | 2 | 2005 | 425 | 0.060 |
Why?
|
| Muscle Weakness | 1 | 2005 | 26 | 0.060 |
Why?
|
| Tiotropium Bromide | 1 | 2014 | 2 | 0.060 |
Why?
|
| Sequence Deletion | 1 | 2005 | 89 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 2007 | 344 | 0.060 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2004 | 34 | 0.060 |
Why?
|
| Occupational Diseases | 1 | 2005 | 68 | 0.060 |
Why?
|
| Fluid Therapy | 1 | 2005 | 59 | 0.060 |
Why?
|
| Hot Temperature | 1 | 2005 | 152 | 0.060 |
Why?
|
| Fever | 1 | 2005 | 96 | 0.060 |
Why?
|
| Bronchiolitis Obliterans | 2 | 1994 | 15 | 0.060 |
Why?
|
| Vital Capacity | 2 | 2020 | 43 | 0.060 |
Why?
|
| Oxazolidinones | 1 | 2004 | 6 | 0.060 |
Why?
|
| Acetamides | 1 | 2004 | 17 | 0.060 |
Why?
|
| Rheumatoid Factor | 1 | 2003 | 21 | 0.060 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2003 | 10 | 0.060 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2003 | 11 | 0.060 |
Why?
|
| Dosage Forms | 1 | 2002 | 20 | 0.050 |
Why?
|
| Esophagectomy | 1 | 2002 | 26 | 0.050 |
Why?
|
| Macrolides | 1 | 2002 | 48 | 0.050 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2001 | 10 | 0.050 |
Why?
|
| Colectomy | 1 | 2022 | 64 | 0.050 |
Why?
|
| Fluoroquinolones | 1 | 2022 | 49 | 0.050 |
Why?
|
| Anti-Anxiety Agents | 1 | 2002 | 107 | 0.050 |
Why?
|
| Gastrointestinal Agents | 1 | 2022 | 51 | 0.050 |
Why?
|
| Benzodiazepines | 1 | 2002 | 130 | 0.050 |
Why?
|
| Esophageal Neoplasms | 1 | 2002 | 150 | 0.050 |
Why?
|
| Solutions | 2 | 2011 | 115 | 0.050 |
Why?
|
| Phonation | 1 | 2020 | 9 | 0.050 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2000 | 20 | 0.050 |
Why?
|
| Voice Training | 1 | 2020 | 7 | 0.050 |
Why?
|
| Area Under Curve | 3 | 2011 | 238 | 0.050 |
Why?
|
| Overweight | 1 | 2022 | 186 | 0.050 |
Why?
|
| Fibrosis | 1 | 2022 | 371 | 0.050 |
Why?
|
| Enteral Nutrition | 1 | 2022 | 157 | 0.050 |
Why?
|
| Vocal Cords | 1 | 2020 | 18 | 0.040 |
Why?
|
| Peer Review, Research | 1 | 2020 | 21 | 0.040 |
Why?
|
| Patients | 1 | 2020 | 69 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2019 | 33 | 0.040 |
Why?
|
| Drug Administration Routes | 1 | 2019 | 25 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2019 | 17 | 0.040 |
Why?
|
| Bronchial Diseases | 1 | 1999 | 9 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2023 | 374 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2020 | 1342 | 0.040 |
Why?
|
| Tissue Donors | 2 | 1998 | 195 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2022 | 346 | 0.040 |
Why?
|
| Adenocarcinoma | 1 | 2002 | 475 | 0.040 |
Why?
|
| Age Factors | 1 | 2004 | 1864 | 0.040 |
Why?
|
| South Carolina | 2 | 2004 | 2752 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 4848 | 0.040 |
Why?
|
| Microbiological Techniques | 1 | 2018 | 9 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2020 | 113 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 352 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2002 | 951 | 0.040 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2018 | 47 | 0.040 |
Why?
|
| Liver Transplantation | 1 | 2001 | 400 | 0.040 |
Why?
|
| Waiting Lists | 1 | 1998 | 104 | 0.040 |
Why?
|
| South Africa | 1 | 2017 | 45 | 0.040 |
Why?
|
| Asia | 1 | 2017 | 59 | 0.040 |
Why?
|
| Health Personnel | 1 | 2020 | 286 | 0.040 |
Why?
|
| Cytochrome P-450 CYP3A Inducers | 1 | 2017 | 1 | 0.040 |
Why?
|
| Pulmonary Medicine | 1 | 2017 | 31 | 0.040 |
Why?
|
| Sample Size | 1 | 2017 | 79 | 0.040 |
Why?
|
| Therapies, Investigational | 1 | 2016 | 6 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2019 | 340 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2002 | 629 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2017 | 289 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 2017 | 184 | 0.030 |
Why?
|
| Blood Gas Analysis | 1 | 1996 | 41 | 0.030 |
Why?
|
| Leukocyte Elastase | 1 | 2015 | 19 | 0.030 |
Why?
|
| Cross-Over Studies | 2 | 2011 | 260 | 0.030 |
Why?
|
| Functional Residual Capacity | 1 | 1995 | 3 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 1998 | 383 | 0.030 |
Why?
|
| Pulmonary Gas Exchange | 1 | 1995 | 20 | 0.030 |
Why?
|
| Vagus Nerve | 1 | 1996 | 90 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2016 | 219 | 0.030 |
Why?
|
| Chloride Channels | 1 | 2015 | 22 | 0.030 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2015 | 48 | 0.030 |
Why?
|
| Preoperative Care | 2 | 1995 | 275 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 652 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2022 | 1615 | 0.030 |
Why?
|
| Gram-Negative Bacteria | 1 | 2014 | 55 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 1994 | 70 | 0.030 |
Why?
|
| Respiratory Paralysis | 1 | 1994 | 10 | 0.030 |
Why?
|
| Bronchoconstrictor Agents | 1 | 2013 | 6 | 0.030 |
Why?
|
| Methacholine Chloride | 1 | 2013 | 20 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 1994 | 78 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 1173 | 0.030 |
Why?
|
| Respiratory Mucosa | 1 | 2013 | 52 | 0.030 |
Why?
|
| Postoperative Care | 1 | 1994 | 163 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2006 | 1447 | 0.030 |
Why?
|
| Heart Transplantation | 1 | 1996 | 328 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 194 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 1266 | 0.030 |
Why?
|
| Diuretics, Osmotic | 1 | 2011 | 5 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2015 | 867 | 0.020 |
Why?
|
| Oxygen | 1 | 1994 | 386 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2011 | 249 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2013 | 1692 | 0.020 |
Why?
|
| Medication Adherence | 1 | 2011 | 335 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 504 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 2550 | 0.020 |
Why?
|
| Epithelial Sodium Channels | 1 | 2005 | 25 | 0.020 |
Why?
|
| Pedigree | 1 | 2005 | 159 | 0.020 |
Why?
|
| Walking | 2 | 2000 | 241 | 0.020 |
Why?
|
| Sodium | 1 | 2005 | 161 | 0.020 |
Why?
|
| Syndrome | 1 | 2005 | 255 | 0.020 |
Why?
|
| Endoscopy | 1 | 2008 | 464 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2005 | 208 | 0.020 |
Why?
|
| Base Sequence | 1 | 2006 | 1015 | 0.010 |
Why?
|
| Linezolid | 1 | 2004 | 7 | 0.010 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2004 | 79 | 0.010 |
Why?
|
| Disinfection | 1 | 2004 | 112 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 1083 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 191 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2004 | 381 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2003 | 99 | 0.010 |
Why?
|
| Animals | 2 | 2013 | 20881 | 0.010 |
Why?
|
| Pulmonary Atelectasis | 1 | 2002 | 12 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 8474 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 2002 | 74 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 1664 | 0.010 |
Why?
|
| Psychological Tests | 1 | 2001 | 96 | 0.010 |
Why?
|
| Personality Assessment | 1 | 2001 | 71 | 0.010 |
Why?
|
| Internal-External Control | 1 | 2001 | 60 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 1174 | 0.010 |
Why?
|
| Breathing Exercises | 1 | 2000 | 8 | 0.010 |
Why?
|
| Reoperation | 1 | 2001 | 467 | 0.010 |
Why?
|
| Exercise Test | 1 | 2000 | 242 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1999 | 334 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2000 | 329 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2001 | 458 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2001 | 403 | 0.010 |
Why?
|
| Mental Health | 1 | 2000 | 278 | 0.010 |
Why?
|
| Anxiety | 1 | 2001 | 422 | 0.010 |
Why?
|
| Half-Life | 1 | 1997 | 96 | 0.010 |
Why?
|
| Liver | 1 | 2001 | 1118 | 0.010 |
Why?
|
| rRNA Operon | 1 | 1994 | 1 | 0.010 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 1994 | 23 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1994 | 44 | 0.010 |
Why?
|
| Bacterial Typing Techniques | 1 | 1994 | 19 | 0.010 |
Why?
|
| DNA, Ribosomal | 1 | 1994 | 59 | 0.010 |
Why?
|
| Exercise | 1 | 2000 | 658 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 1994 | 150 | 0.010 |
Why?
|
| Depression | 1 | 2001 | 943 | 0.010 |
Why?
|
| Schools, Medical | 1 | 1995 | 157 | 0.010 |
Why?
|
| Models, Biological | 1 | 1997 | 981 | 0.010 |
Why?
|